866-997-4948(US-Canada Toll Free)

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 48 Pages

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)-Pipeline Review, H2 2017

Summary

According to the recently published report Cholesteryl Ester Transfer Protein-Pipeline Review, H2 2017; Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)-Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein is a plasma protein that promotes the transfer of cholesteryl esters from anti-atherogenic HDLs to proatherogenic apolipoprotein B (apoB)-containing lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs. A deficiency of CETP is associated with increased HDL levels and decreased LDL levels, a profile that is typically anti-atherogenic.

The report Cholesteryl Ester Transfer Protein-Pipeline Review, H2 2017 outlays comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular and Metabolic Disorders which include indications Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease, Coronary Disease and Hyperlipidemia.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
- The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)-Overview
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)-Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)-Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)-Companies Involved in Therapeutics Development
Amgen Inc
Chong Kun Dang Pharmaceutical Corp
Kowa Co Ltd
Pfizer Inc
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)-Drug Profiles
AMG-899-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-508-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CKD-519-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dalcetrapib-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-16-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-312-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04445597-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CETP for Dyslipidemia-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)-Dormant Products
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)-Discontinued Products
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)-Product Development Milestones
Featured News & Press Releases
Aug 28, 2017: DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial
Mar 07, 2017: DalCors Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule
Nov 10, 2016: DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans
Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial
Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics
Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial
Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery
Jun 03, 2015: Dezima Pharmas CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet
Jan 12, 2015: A World First-Discovery of a personalized therapy for cardiovascular disease
Nov 13, 2014: Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein (a) Levels
Aug 29, 2014: Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia
Jul 08, 2014: Dezima Pharma extends clinical development program for its CETP Inhibitor TA-8995
Jan 13, 2014: Dezima Pharma Completes Patient Enrolment for TULIP Phase 2B Study with CETP Inhibitor TA-8995
Aug 29, 2013: Dezima Pharma initiates Phase 2b TULIP study on CETP inhibitor program DEZ-001
Nov 05, 2012: Roches Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Amgen Inc, H2 2017
Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
Pipeline by Kowa Co Ltd, H2 2017
Pipeline by Pfizer Inc, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017
Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *